Floatz logo

OTL-38

Malignant Abdominal Neoplasm

Mayo ClinicSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Malignant Abdominal Neoplasm cohort.

Asset / SponsorPhaseRating
ERIBULIN MONOMETHANESULFONATE
OHSU Knight Cancer Institute
Phase 1CC
Bms-907351
M.D. Anderson Cancer Center
Phase 1CC
Atezolizumab
M.D. Anderson Cancer Center
Phase 1CC
Sodium Thiosulfate
Mayo Clinic
Early Phase 1C
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Early Phase 1C
Inno-206
Mayo Clinic
Early Phase 1C

Same molecule, other indications

OTL-38 is also rated in:

ovarian cancerDormant
BB
Indicative ·
67 / 100
View asset →
lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
childhood malignant neoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →